Vincent K. Tuohy, Ph.D.

Staff

The Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research

Lerner Research Institute
9500 Euclid Avenue
Cleveland, Ohio 44195
Location:NB3-76
tuohyv@ccf.org
Phone: (216) 445-9684
Fax: (216) 444-8372



We have had a longstanding interest in understanding the precise self-recognition events involved in initiation and progression of autoimmune diseases and in developing novel therapeutic strategies that prevent disease progression. In these pursuits we have developed and characterized autoimmune animal models for several human diseases including multiple sclerosis, heart failure, sudden hearing loss, infertility, prostatitis, interstitial cystitis/pelvic pain syndrome, and breast failure. However, more recently, we have focused our attention on harnessing and focusing the full strength of the autoimmune response to provide safe and effective immunity against the development of diseases we confront with age. As such we have pioneered the concept of ‘immunoprevention’ of breast cancer by providing proof-of-principle that safe and effective protection against the development of breast cancer may be induced by vaccination against ‘retired’ self-proteins that are no longer expressed with age at immunogenic levels in any normal tissues but are overexpressed in newly invigorated emerging breast tumors. Thus, ‘retired’ proteins may substitute for unavailable pathogens as targets for developing prophylactic immunity against tumors we confront with age like breast, ovarian, and prostate cancer. Our laboratory is currently involved in bringing our ‘immunoprevention’ strategy from bench-to-bedside in clinical trials designed to prevent the more aggressive and lethal forms of breast cancer.

In other words ...

Current Program: 

  • Cancer Vaccines
  • Cancer Immunotherapy
  • Primary Immunoprevention of Breast Cancer
  • Primary Immunoprevention of Ovarian Cancer
  • Plasticity of Self-Recognition in Autoimmune Disease
  • Immunoregulation of Autoimmunity
Investigators: 
  • Li-Xin Wng, M.D., Ph.D. Staff Scientist
  • Suparna Mazumder, Ph.D., Project Scientist
  • Roberto Aguilar, Ph.D., Visiting Scientist
  • Justin M. Johnson, B.S., Senior Research Technologist, Graduate Student, and Ph.D. Candidate
  • Dennis J. Wilk, B.Sc., Senior Rsearch Technologist 
  • Valerie Swank, B.S., Research Technologist
  • Patrick Barrett, B.S., Research Technologist
Collaborators:
  • G. Thomas Budd, M.D., Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
  • Joseph Crowe, M.D., Director of the Breast Center and Breast Services, Cleveland Clinic, Cleveland, OH


Robert  Aguilar
Robert Aguilar
Visiting Scientist

Location:NN1-15
Phone:(216) 444-0613
aguilar@ccf.org
laboratory

Patrick  Barrett
Patrick Barrett
Research Technologist

Location:NN1-15
Phone:(216) 444-0613
barretp@ccf.org
laboratory

Justin M. Johnson
Justin M. Johnson
Principal Research Technologist

Location:NN1-15
Phone:(216) 444-0613
johnsoj1@ccf.org
Fax:(216) 444-8372
laboratory

Suparna  Mazumder Ph.D.
Suparna Mazumder Ph.D.
Project Staff

Location:NB3-26
Phone:(216) 444-0613
mazumds@ccf.org
laboratory

Valerie Ann Swank
Valerie Ann Swank
Sr. Research Technologist

Location:NN1-15
Phone:(216) 444-0613
swankv@ccf.org
Fax:(216) 444-8372
laboratory

Li-Xin  Wang M.D., Ph.D.
Li-Xin Wang M.D., Ph.D.
Staff Scientist

Location:NE6-251
Phone:(216) 445-5273
wangl3@ccf.org
laboratory


Recent Key References

Tuohy VK, Jaini R, Johnson JM, Loya MG, Wilk D, Downs-Kelly E, Mazumder S. Targeted vaccination against human α-lactalbumin for immunotherapy and primary immunoprevention of triple negative breast cancer. Cancers (in press)

Tuohy VK. Primary immunoprevention: The great unmet need for controlling breast cancer. Oncology (Williston Park) 2016; 30(5):pii: 217055

Sakalar C, Mazumder S, Johnson JM, Altuntas CZ, Jaini R, Aguilar R, Naga Prasad SV, Connolly DC, Tuohy VK. Regulation of murine ovarian epithelial carcinoma by vaccination against the cytoplasmic domain of anti-Müllerian hormone receptor II. Journal of Immunology Research 2015; 2015:630287

Emens LA, Tuohy VK, Stanton SE, Clarke E. Immunotherapy for breast cancer: is it feasible? Immunotherapy 2015; 7:1135-1143

Jaini R, Altuntas CZ, Loya MG, Tuohy VK. Disruption of estrous cycle homeostasis in mice with experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2015; 279:71-74

Tuohy VKBench-to-bedside challenges in developing immune protection against breast cancer. Cleveland Clinic Journal of Medicine 2014; 81:605-607

Bicer F, Altuntas CZ, Izgi K, Ozer A, Kavran M, Tuohy VK, Daneshgari F. Chronic pelvic allodynia is mediated by CCL2 through mast cells in an experimental autoimmune cystitis model. American Journal of Physiology: Renal Physiology 2015; 308:F103-113

Tuohy VKRetired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers. Expert Review of Vaccines 2014; 13:1447-1462

Singh V, Jaini R, Torricelli AA, Tuohy VK, Wilson SE. A method to generate enhanced GFP+ chimeric mice to study the role of bone marrow-derived cells in the eye. Experimental Eye Research 2013; 116:366-370

Jaini R, Rayman P, Cohen PA, Finke JH, Tuohy VKCombination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. International Journal of Cancer 2014; 134:1695-1705

Izgi K, Altuntas CZ, Bicer F, Ozer A, Sakalar C, Li X, Tuohy VK, Daneshgari F. Uroplakin peptide-specific autoimmunity initiates interstitial cystitis/painful bladder syndrome in mice. PLoS One 2013; 8:e72067

Jaini R, Popescu DC, Flask CA, Macklin WB, Tuohy VKMyelin antigen load influences antigen presentation and severity of central nervous system autoimmunity. Journal of Neuroimmunology 2013; 259:37-46

Altuntas CZ, Daneshgari F, Veizi E, Izgi K, Bicer F, Ozer A, Grimberg KO, Bakhautdin B, Sakalar C, Tasdemir C, Tuohy VKA novel murine model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by immunization with a spermine binding protein (p25) peptide. American Journal of Physiology: Regulation, Integrative, and Comparative Physiology 2013; 304:R415-422

Altuntas CZ, Daneshgari F, Izgi K, Bicer F, Ozer A, Sakalar C, Grimberg KO, Sayin I, Tuohy VKConnective tissue and its growth factor CTGF distinguish the morphometric and molecular remodeling of the bladder in a model of neurogenic bladder. American Journal of Physiology: Renal Physiology 2012; 303:F1363-1369

Kesaraju P, Jaini R, Johnson JM, Altuntas CZ, Gruden JJ, Sakalar C, Tuohy VK. Experimental autoimmune breast failure: a model for lactation insufficiency, postnatal nutritional deprivation, and prophylactic breast cancer vaccination. American Journal of Pathology 2012; 181:775-784

Altuntas CZ, Daneshgari F, Sakalar C, Goksoy E, Gulen MF, Kavran M, Qin J, Li X, Tuohy VKAutoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. European Urology 2012; 61:193-200

Altuntas CZ, Jaini R, Kesaraju P, Jane-wit D, Johnson JM, Covey K, Flask CA, Dutertre M, Picard JY, Tuohy VKAutoimmune mediated regulation of ovarian tumor growth. Gynecologic Oncology 2012; 124:98-104

Altuntas CZ, Daneshgari F, Sakalar C, Goksoy E, Gulen MF, Kavran M, Qin J, Li X, Tuohy VKAutoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. European Urology 2012; 61:193-200

Tuohy VK, Jaini R. Prophylactic cancer vaccination by targeting functional non-self. Annals of Medicine 2011; 43:356-365

Tuohy VKA prophylactic vaccine for breast cancer? Why not? Breast Cancer Research 2010; 12:405

Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VKAn autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nature Medicine 2010; 16:799-803

Kang Z, Altuntas CZ, Gulen MF, Liu C, Giltiay N, Qin H, Liu L, Qian W, Ransohoff RM, Bergmann C, Stohlman S, Tuohy VK, Li X. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitisImmunity 2010; 32:414-425

Gulen MF, Kang Z, Bulek K, Youzhong W, Kim TW, Chen Y, Altuntas CZ, Sass Bak-Jensen K, McGeachy MJ, Do JS, Xiao H, Delgoffe GM, Min B, Powell JD, Tuohy VK, Cua DJ, Li X. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 2010; 32:54-66

Staschke KA, Dong S, Saha J, Zhao J, Brooks NA, Hepburn DL, Xia J, Gulen MF, Kang Z, Altuntas CZ, Tuohy VK, Gilmour R, Li X, Na S. IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease. Journal of Immunology 2009; 183:568-577

Tigno-Aranjuez JT, Jaini R, Tuohy VK, Lehmann PV, Tary-Lehmann M. Encephalitogenicity of complete Freund's adjuvant relative to CpG is linked to induction of Th17 cells. Journal of Immunology 2009; 183:5654-5661

Buniel MC, Geelan-Hansen K, Weber PC, Tuohy VKImmunosuppressive therapy for autoimmune inner ear disease. Immunotherapy 2009; 1:425-434